Remacemide hydrochloride

Discontinued Product

Remacemide hydrochloride (Cat. No. 1622) has been withdrawn from sale for commercial reasons.
Description: NMDA antagonist; blocks ion channel and allosteric modulatory site
Alternative Names: FPL 12924AA
Chemical Name: 2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for Remacemide hydrochloride

Remacemide hydrochloride is an non-competitive NMDA receptor antagonist; blocks ion channel and allosteric modulatory site (IC50 = 8 - 68 mM). Remacemide hydrochloride is anticonvulsant in vivo and metabolizes to a more potent desglycine analog. Weakly blocks voltage-dependent Na+ channels (IC50 = 161 mM). In an animal model of Huntington's disease, extends survival and delays disease; this effect is more pronounced when combined with Coenzyme Q10 (Cat. No. 3003)

Licensing Information

Sold with the permission of AstraZeneca UK Ltd.

Technical Data for Remacemide hydrochloride

M. Wt 304.82
Formula C17H20N2O.HCl
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 111686-79-4
PubChem ID 60510
InChI Key HYQMIUSWZXGTCC-UHFFFAOYSA-N
Smiles Cl.CC(CC1=CC=CC=C1)(NC(=O)CN)C1=CC=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Remacemide hydrochloride

References for Remacemide hydrochloride

References are publications that support the biological activity of the product.

Palmer et al (1995) Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann.N.Y.Acad.Sci. 765 236 PMID: 7486610

Santangeli et al (2002) Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur.J.Pharmacol. 438 63 PMID: 11906711

Subramaniam et al (1996) Block of the N-MthD.-aspartate receptor by remacemide and its des-glycine metabolite. J.Pharmacol.Exp.Ther. 276 161 PMID: 8558426

Ferrante et al (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J.Neurosci. 22 1592 PMID: 11880489

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: Remacemide hydrochloride, Remacemide hydrochloride supplier, NMDA, antagonists, blocks, ion, channel, allosteric, modulatory, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, AstraZeneca, FPL, 12924AA, 1622, Tocris Bioscience

Citations for Remacemide hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for Remacemide hydrochloride.

Reviews for Remacemide hydrochloride

There are currently no reviews for this product. Be the first to review Remacemide hydrochloride and earn rewards!

Have you used Remacemide hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.